Results 21 to 30 of about 16,159 (251)

CLINICAL AND SOCIAL RISK FACTORS OF TARDIVE DYSKINESIA IN PATIENTS WITH SCHIZOPHRENIA DURING ANTIPSYCHOTIC TREATMENT

open access: yesБюллетень сибирской медицины, 2015
The purpose of the present work was to study the clinical features and risk factors of tardive dyskinesia among     the     schizophrenia     patients     who     durably     receive     the     antipsychotic     therapy.
Ye. G. Kornetova   +4 more
doaj   +1 more source

ATP Signaling Controlling Dyskinesia Through P2X7 Receptors

open access: yesFrontiers in Molecular Neuroscience, 2020
Dopamine replacement therapy with L-3,4-dihydroxyphenylalanine (L-DOPA) is the only temporary therapy for Parkinson’s disease (PD), but it triggers dyskinesia over time.
Analu A. Fonteles   +8 more
doaj   +1 more source

Post-cholecystectomy syndrome: A new look at an old problem

open access: yesJournal of Minimal Access Surgery, 2018
Background: Despite being the most commonly performed operations, sometimes cholecystectomy fails to relieve symptoms; this is now a well-recognised clinical entity termed 'post-cholecystectomy syndrome' (PCS).
Divya Arora   +3 more
doaj   +1 more source

Rare form of dyskinetic movements associated with alcohol withdrawal

open access: yesIndian Journal of Psychological Medicine, 2016
Movement disorders are known to occur during alcohol withdrawal. Tremor, choreoathetosis, transient parkinsonism, myoclonus and dystonia have been previously described. The present report describes involuntary ′fluttering′ movements of fingers developing
Sathya Prakash, Yatan Pal Singh Balhara
doaj   +1 more source

Dyskinesias arsenicaes [PDF]

open access: yesThe Journal of Nervous and Mental Disease, 1898
n ...
openaire   +2 more sources

Amantadine ER (Gocovri®) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's Disease

open access: yesFrontiers in Neurology, 2021
Background: Clinical trials for antiparkinsonian drugs aimed at managing motor complications typically use patient diaries to divide levodopa-induced dyskinesias (LID) into “troublesome” and “non-troublesome” categories.
Robert A. Hauser   +4 more
doaj   +1 more source

Primary ciliary dyskinesia: current state of the art

open access: yes, 2007
Primary ciliary dyskinesia (PCD) is usually inherited as an autosomal recessive, and in classical form presents with upper and lower respiratory tract infection, and mirror image arrangement in around 50% cases.
Hall, Pippa   +10 more
core   +1 more source

Levosulpiride-induced neurological adverse effects: A prospective study from a tertiary care center

open access: yesAnnals of Indian Academy of Neurology, 2020
Background: Levosulpiride (LS) is a prokinetic drug increasingly used for the gastric motility disorders. Despite its common use for the gastric motility disorder, the tendency to cause parkinsonism and acute dystonias are under-recognized as the major ...
Jacob Joe
doaj   +1 more source

Glutamatergic Tuning of Hyperactive Striatal Projection Neurons Controls the Motor Response to Dopamine Replacement in Parkinsonian Primates

open access: yesCell Reports, 2018
Dopamine (DA) loss in Parkinson’s disease (PD) alters the function of striatal projection neurons (SPNs) and causes motor deficits, but DA replacement can induce further abnormalities.
Arun Singh   +7 more
doaj   +1 more source

Primary ciliary dyskinesia: a national expert consensus statement on standards of care

open access: yesERJ Open Research
Primary ciliary dyskinesia (PCD) is a genetically and clinically diverse disorder characterised by loss of normal ciliary function leading to chronic oto-sino pulmonary disease, situs abnormalities and subfertility in men and women.
Evie A. Robson   +17 more
doaj   +1 more source

Home - About - Disclaimer - Privacy